




Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome
after allogeneic hematopoietic stem cell transplantation for
myelofibrosis: a study of the CMWP of EBMT
Nicolaus Kröger 1 ● Giulia Sbianchi2 ● Tiarlan Sirait3 ● Christine Wolschke1 ● Dietrich Beelen4 ● Jakob Passweg5 ●
Marie Robin 6 ● Radovan Vrhovac7 ● Grzegorz Helbig8 ● Katja Sockel 9 ● Eibhlin Conneally10 ●
Marie Thérèse Rubio11 ● Yves Beguin12 ● Jürgen Finke13 ● Paolo Bernasconi14 ● Elena Morozova15 ●
Johannes Clausen 16 ● Peter von dem Borne17 ● Nicolaas Schaap18 ● Wilfried Schroyens19 ● Francesca Patriarca20 ●
Nicola Di Renzo 21 ● Zeynep Arzu Yeğin22 ● Patrick Hayden23 ● Donal McLornan 24 ● Ibrahim Yakoub-Agha 25
Received: 25 January 2021 / Revised: 7 April 2021 / Accepted: 29 April 2021
© The Author(s) 2021. This article is published with open access
Abstract
JAK1/2 inhibitor ruxolitinib (RUX) is approved in patients with myelofibrosis but the impact of pretreatment with RUX on
outcome after allogeneic hematopoietic stem cell transplantation (HSCT) remains to be determined. We evaluated the impact
of RUX on outcome in 551 myelofibrosis patients who received HSCT without (n= 274) or with (n= 277) RUX
pretreatment. The overall leukocyte engraftment on day 45 was 92% and significantly higher in RUX responsive patients
than those who had no or lost response to RUX (94% vs. 85%, p= 0.05). The 1-year non-relapse mortality was 22% without
significant difference between the arms. In a multivariate analysis (MVA) RUX pretreated patients with ongoing spleen
response at transplant had a significantly lower risk of relapse (8.1% vs. 19.1%; p= 0.04)] and better 2-year event-free
survival (68.9% vs. 53.7%; p= 0.02) in comparison to patients without RUX pretreatment. For overall survival the only
significant factors were age > 58 years (p= 0.03) and HLA mismatch donor (p= 0.001). RUX prior to HSCT did not
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The BCR-ABL1-negative myeloproliferative neoplasms
primary myelofibrosis (PMF) and advanced forms of
essential thrombocythemia and polycythemia vera (i.e.,
post ET/PV myelofibrosis) are chronic hematological
malignancies characterized by splenomegaly, leukoery-
throblastosis, extramedullary hematopoiesis and con-
stitutive mobilization of CD34-positive progenitor cells.
Patients with symptomatic PMF have a median survival of
<5 years [1].
Before the introduction of JAK-inhibitor ruxolitinib
(RUX), conventional therapies for treatment of PMF/MF
included the use of growth factors such as erythropoietin,
androgens, immune-modulating drugs, interferon-alpha,
cytoreductive agents, and non-pharmacological options
such as blood transfusion, spleen irradiation, and sple-
nectomy. None of these approaches have shown to prolong
patient survival. Allogeneic stem cell transplantation
(HSCT) is the only currently available therapy with curative
potential for MF, resulting in resolution of bone marrow
fibrosis, molecular remission, and restoration of normal
hematopoiesis [2].
However, allo-SCT is associated with a significant
mortality and the European Leukemia Network (ELN)
recommends consideration of allo-SCT in patients with a
life expectancy of <5 years (i.e., intermediate II and high
risk according to IPSS) [3].
JAK2V617F mutation is an acquired point mutation in
the pseudo-kinase domain of the Janus kinase-2, which
confers a constitutive JAK2 pathway activation with
resulting growth factor independent proliferation of myeloid
precursors [4, 5].
Ruxolitinib (RUX) is the first JAK inhibitor approved by
the U.S. Food and Drug Administration for use in patients
with intermediate- or high-risk MF (primary MF, Post PV/
ET-MF) and in Europe for symptomatic MF patients with
splenomegaly, regardless of the IPSS risk classification.
RUX, a JAK1/ JAK2 inhibitor, showed early and sustained
clinical benefits in patients with intermediate-2 and high-
risk MF, including spleen size reduction and improvement
of constitutional symptoms in a phase 1/2 trial
(INCB18424-251) and the phase 3 trials COMFORT-I and
COMFORT-II independent on JAK mutation status [6–8].
A survival benefit with RUX was shown in the COMFORT-
I and COMFORT-II analyses [9, 10].
However, JAK inhibition only marginally targets the
malignant clone and thus cannot be considered as curative
treatment. Because spleen size may have significant impact
on engraftment and graft function [11] and constitutional
symptoms are a major risk factor for mortality [12], JAK
inhibitor treatment prior to HSCT may be a reasonable
option to decrease spleen size and improve constitutional
symptoms in order to reduce therapy-related complications
after stem cell transplantation.
This large retrospective international registry study of the
European Society of Blood and Marrow Transplantation
(EBMT) aimed to analyze the impact of RUX treatment
prior to HSCT on outcome such as engraftment, graft-
versus-host disease (GVHD), non-relapse mortality (NRM),
relapse and overall survival (OS) in comparison compared




This is a retrospective study utilizing registry data of
EBMT. A preceding survey was done to invite EBMT’s
center members to participate in this study and to identify
eligible patients. Related variables which already exists in
EBMT registry was extracted in June 2018. Thereafter pre-
filled electronic forms were built in Microsoft excel incor-
porating all essential variables and existing variables from
EBMT’s registries when applicable. The electronic forms
were sent to centers which previously confirmed participa-
tion in this study. Major research objectives were to eval-
uate the impact of pretreatment RUX on spleen size,
engraftment, NRM, GVHD, relapse incidence (RI), 2-year
event-free and OS.
Major inclusion criteria were: Patients with PMF or
myelofibrosis post polycythemia vera or essential throm-
bocythemia, allogeneic hematopoietic stem cell transplan-
tation (HSCT) from related or unrelated donor matched or
mismatched donor between 2012 and 2016 with or without
RUX treatment prior to transplantation, aged 18–75 years
and written informed consent. We included only patients
who did receive RUX prior to conditioning. Patients with
RUX through the transplant or posttransplant were not
included in this analysis
Statistical methods
Baseline variables consist of information available at time
of HSCT. Continuous variables are summarized by report-
ing the number of patients with available data, median, and
range. Categorical information has been reported showing
the number of patients with available data, frequencies and
percentages. For the calculation of percentages, the
denominator has been determined by the number of avail-
able cases of the respective variable. Mann–Whitney or
Kruskal–Wallis test have been used to compare continuous
predictors among RUX and non-RUX treated cases and
Chi-Squared or Fisher Exact Test for categorical data.
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Outcome variables consider information available only
after HSCT. The study aims to compare the following
outcomes post – HSCT:
Non-relapse mortality (NRM), defined as the time from
transplant until death from any cause without prior relapse/
progression occurrence; relapse is considered as competing
event. Relapse incidence (RI), defined as the time from
HSCT until the first relapse or progression. Death without
prior relapse/progression is a competing event. Event-free
survival (EFS), defined as the time from HSCT until
relapse, disease progression, or death, whichever occurs
first. Overall survival (OS), defined as the time from HSCT
until death from any cause. Acute GVHD, defined as the
time from transplant until acute GvHD occurrence by day
100; death without prior acute GVHD is the competing
event. Chronic GVHD, defined as the time from transplant
until chronic graft disease occurrence from day 100; death
without prior chronic GVHD is the competing event. Cases
still alive are censored at the time of last follow-up. Time to
Engraftment was defined as median days to neutrophil
(>1.0 × 10e9/L) and platelet (>20 × 10e9/L).
For OS and EFS, the Kaplan–Meier estimates have been
produced and groups have been compared using the Log-
Rank test. The Cox proportional hazards (PH) regression
model has been used to investigate the role of continuous
prognostic factors and to get adjusted hazard ratios. The
above outcomes are reported and compared, where possible,
at 24 months post-HSCT.
Spleen response was defined as at least 25% reduction in
spleen size, <25% was defined as no response. Within the
group of responders more or <50% were also distinguished.
For all other endpoints methods for competing risks have
been applied. In particular, crude cumulative incidence
curves have been produced, and groups have been com-
pared by the Gray test. Adjusted analyses of the cause-
specific hazards have been performed using the Cox PH
model. The above outcomes are reported and compared,
where possible, at 12 or 24 months post-HSCT, according
to the study objective indication.
Factors showing a significant impact on the outcome or
highly associated with RUX treatment have been included
in the final model.
In order to take into account possibly unmeasured con-
founders related to the fact of belonging to the same center,
adjusted effects on outcomes have been estimated in terms
of hazard ratios using the Cox model with a shared random
center effect (“Frailty Model”).
In order to further investigate the role of the different
length of the time intervals between diagnosis and trans-
plant in the two groups, RUX and no RUX cases, on sur-
vival like endpoints, adjusted hazard ratios for OS and EFS
have been estimated using model for left truncated data. The
triplet given by the transplant time, the survival since
diagnosis and the endpoint specific status was taken as
outcome variable. As a further step, Poisson regression
models for multiple time scales have been applied to asses
and evaluate the impact of both time scales, the interval
time diagnosis and transplant and the follow up from
transplant onwards. As these analyses have not provided
any significant results, data are not shown.
All outcomes are reported either with a survival or
cumulative incidence plot. Tables of survival and cumula-
tive incidence estimates at the specified time points also
report numbers of patients at risk and 95% confidence
intervals (CI). 95% CI are also reported for hazard ratios
from Cox regression. All comparisons are reported with an
associated p value, and p values < 0.05 are considered sta-
tistically significant.
The quality of follow-up in the entire cohort has been
determined using the reverse Kaplan–Meier method, pro-
viding the median follow-up time and associated 95%
confidence interval.
The frequency of missing cases is displayed in the fre-
quency table of the corresponding variable. These counts of
missing cases have not been included in the calculation of
any of the percentages, test statistics or subsequent p values.
In case data were missing for a specific variable, the number
of patients contributing to that variable have been lower
than the number of patients in the respective cohort. Where
necessary, in order to avoid reduction of sample size, cases
with missing information have been included by adding the
missing category for factors included in Cox model.
Results
Fifty-eight EBMT centers participated in the study and
completed the electronic forms. Of those centers, 586
patients’ data were received. Thirty-five patients were
excluded due to inclusion of ongoing clinical trials, trans-
formation to other malignancies before allo-SCT, having
syngeneic donor and error diagnosis information entered in
the registry. In total, 551 patients were included on which
two hundred seventy-seven patients received RUX treat-
ment prior to allo-SCT. The patient’s characteristics at study
entry are listed in Table 1. In the RUX arm there were more
intermediate II and fewer intermediate I patients and more
JAK2-negative patients. MUD and Karnofsky score of ≤80
were more frequently seen in RUX pretreated patients. In
addition the interval from diagnosis to transplantation was
significantly longer in the RUX pretreated arm.
Out of 551 cases, 277 received RUX at any time prior to
transplantation and 274 did not receive RUX. The major
characteristics of the RUX pretreated cohort regarding
treatment duration, dosing and response are listed in
Table 2. The median spleen size at start of RUX was 12 cm
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below left costal arch and the median spleen size in the
RUX treated group at time of transplantation was 10 cm
while in the non-RUX group the median spleen size was 8
cm at time of transplantation.
In order to compare outcome results after allogeneic stem
cell transplantation in more detail, the RUX pretreatment
group was divided into ongoing spleen response (n= 91)
with spleen response ≥ 50% (n= 25) and spleen response
<50% (n= 66), or no ongoing spleen response (n= 104):
either loss of spleen response (n= 23) or no spleen response
at all (n= 81).
Engraftment/graft failure
The median time to neutrophil engraftment for the entire
study population was 17 days (range, 5–83) and for platelets
21 days (range, 3–413). For the non-RUXO treated patients
the median neutrophil and platelet engraft was 17 (range
7–57) and 20 (range 3–413) days, respectively. For RUXO
responsive patients the neutrophil and platelet engraftment
was noted after a median of 16 (range 5–54) and 20
(range 6–395) days, while for patient who had no or lost
response to RUXO the median time for neutrophil and
platelet engraftment was 17 (range 10–81) (p= 0.43) and
25/range 5–198) days (p= 0.005), respectively. (Fig. 1 and
Table 3)
Table 1 Patients characteristics at study entry (n= 551).
Prior RUX No RUX p= value
Number of patients n= 277 (50.3%) n= 274 (49.7%)
Median age (range) 58 (30–75) 58 (29–75) p= 0.4
Patients gender (n= 551)
Male n= 175 (63%) n= 173 (63%) p= 0.9
Female n= 102 (37%) n= 101 (37%)
DIPSS at transplant (n= 421, 76%)
Low n= 2 (1%) n= 11 (6%) p < 0.01
Intermediate-1 n= 48 (21%) n= 69 (35%)
Intermediate-2 n= 125 (56%) n= 76 (39%)
High risk n= 49 (22%) n= 41 (20%)
JAK (n= 354, 64%)
Positive n= 154 (79%) n= 134 (86%) p= 0.05
Negative n= 44 (21%) n= 22 (14%)
Donor (n= 551, 100%)
MRD n= 66 (24%) n= 100 (36%) p= 0.003
MUD n= 192 (69%) n= 150 (55%)
MMUD/MMRD n= 19 (7%) n= 26 (9%)
CMV status (n= 533, 97%)
+/+ n= 113 (41%) n= 108 (41%) p= 0.56
+/− n= 46 (20%) n= 55 (21%)
−/− n= 90 (33%) n= 75 (29%)
−/+ n= 23 (9%) n= 23 (9%)
Disease (n= 551, 100%)
Primary myelofibrosis n= 185 (67%) n= 199 (73%) p= 0.1
Post-ET/-PV n= 92 (33%) n= 75 (27%)
Median follow-up (months) 44 (6–87) 49 (2–91) p < 0.01
Conditioning regimen (n= 548, 99%)
RIC n= 187 (67%) n= 164 (60%) p= 0.08
MAC n= 90 (33%) n= 107 (40%)
Spleen size at transplant
(palpable in cm) (n= 305)
10 (1–30) 8 (1–30) p= 0.4
Constitutional symptoms at
transplant (n= 297, 55%)
n= 159 (68%) n= 138 (61%) p= 0.1
Donor source (n= 551, 100%)
BM n= 21 (8%) n= 23 (7.6%) p= 0.9
PB n= 255 (91.6%) n= 250 (91%)
CB n= 1 (0.4%) n= 1 (0.4%)
Karnofsky at transplant (n= 537, 97%)
≤80 n= 113 (42%) n= 89 (33%) p= 0.03
≥90 n= 154 (58%) n= 181 (67%)
Interval from diagnosis to
transplant (months)
68 (2–430) 32 (2–527) p < 0.01
Table 2 Ruxolitinib treatment prior to allograft (n= 277).
Discontinuation of RUX prior to allograft (for
reasons other than transplant) (n= 245, 88%)
n= 56 (23%)
Tapering of RUX prior to discontinuation (n= 245, 88%)
Yes n= 117 (48%)
No n= 128 (52%)
Median starting dose of RUX/day 30 mg (range: 5–80)
Median dose at last period/day 20 mg (range: 5–50)
Reasons of early discontinuation (n= 56, 100%)
No response n= 16 (29%)
Loss of response n= 5 (9%)
Toxicity n= 13 (23%)
Others n= 22 (39%)
Rebound phenomenon after stopping RUX
(n= 245, 88%)
n= 15 (6%)
Median spleen size at start of RUX (palpable in
cm) (n= 141, 51%)
12 cm (1–32)
Constitutional symptoms at start of RUX (n= 219, 79%)
Yes n= 190 (87%)
No n= 29 (13%)
Best response to RUX (n= 227, 82%)
Spleen size > 50% n= 39 (17%)
Spleen size < 50% n= 88 (39%)
No response n= 100 (44%)
Response of RUX to spleen size at time of transplant (n= 195, 70%)
Spleen response > 50% n= 25 (13%)
Spleen response < 50% n= 66 (34%)
Lost spleen response n= 23 (12%)
No spleen response n= 81 (42%)
Median duration of RUX treatment (months)
(n= 219, 79%)
7.6
Infections during RUX treatment (n= 277, 100%)
Yes n= 25 (11%)
No n= 210 (89%)
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Graft-versus-host disease and CMV reactivation
The incidence of acute GVHD grade II–IV for the entire
study population was 28.9% (95% CI: 25.1–32.8) and did
not differ between the non-RUX (28.9%) (95% CI:
23.4–34.4) and RUX treatment (29.0%) (95% CI:
23.6–34.4) (p= 0.99), despite more patient in the RUX arm
received unrelated donor grafts. The incidence of severe
aGVHD II–IV did also not differ between, RUX-responsive
(27.0%) (95% CI: 17.7–36.2) and no or lost response to
RUX group (27.5%) (95% CI: 18.8–36.1) (p= 0.92).
The cumulative incidence of overall chronic GVHD at 2
years for the entire study population was 46.7% (95% CI:
42.2–51.2) and was significantly lower in the non-RUX arm
(41.7%) (95% CI: 35.4–48.0) compared to the RUX arm
(51.4%) (95% CI: 45.1–57.7) (p= 0.05). The incidence of
cGVHD did not differ between RUX-responsive (50.7%)
(95% CI: 40.0–61.3) and no or lost response to RUX group
(55.7%) (95% CI: 45.2–66.2) (p= 0.11).
Chronic GVHD extensive disease was noted in 25.5%
(95% CI: 19.8–31.1) in the non-RUX, 37.9% (95% CI:
27.5–48.3) in the no or lost response group, and 30.6%
(95% CI: 20.8–40.4) in the RUX responsive group (p=
0.08) (Table 3).
Overall 31.7% experienced CMV reactivation after stem
cell transplantation. Patients at risk (serostatus CMV posi-
tive) had a non-significant higher risk of CMV reactivation
in the RUX pretreated arm (36.6% vs. 26.8%, p= 0.07).
Non-relapse mortality (NRM)
The cumulative incidence of NRM at 1 year was 21.9%
(95% CI: 18–25) and did not differ significantly in an
univariate analysis between the non-RUX (22.9%) (95% CI:
18–28) vs. no or lost response to RUX (25.5%) (95% CI:
17–34) and the RUX responsive group (14.8%) (95% CI:
Fig. 1 Engraftment after stem cell transplantation according Ruxo
pretreatment. Neutrophil engraftment after allogeneic stem cell
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7–22) (p= 0.16) (Table 3). In a multivariate analysis
(MVA) including RUX vs. non-RUX pretreatment the HR
for RUX pretreatment was 0.80 (p= 0.32) (Table 4A),
while ongoing spleen response vs. no/lost response showed
a HR of 0.56 (p= 0.07). Higher age (>58 y) resulted in a
HR of 1.46 (p= 0.07) while the only significant factor for a
higher NRM in the MVA was HLA-mismatched donor (HR
2.79, p= 0.002) (Table 4A).
Relapse
The cumulative incidence of relapse at 2 years for the entire
study population was 16.3% and in patients with RUX
pretreatment not significantly lower than in the non-RUX
pretreated group: 13.7% (95% CI: 9.6–17.8) vs. 19.1%
(95% CI: 14.3–23.9) (p= 0.09) (Fig. 2). The incidence of
relapse at 2 years significantly differed between RUX
responsive (8.1%; 95% CI: 2.3–13.8) patients and those
who had no or lost response (15.7%; 95% CI: 8.6–22.7)
(p= 0.05). In a MVA including RUX vs. non-RUX pre-
treatment the HR for RUX pretreatment was 0.68 (95%
CI:0.41–1.11) (p= 0.12) (Table 4A), while ongoing spleen
response vs. no/lost response showed a HR of 0.41 (95%
CI: 0.15–1.09) (p= 0.07) and ongoing spleen response vs.
non-RUX showed a HR of 0.34 (95% CI: 0.12–0.95, p=
0.04), which was the only significant factor in the MVA for
relapse (Table 4B).
Event-free survival
The EFS for the entire study population at 2 years was
56.5% (95% CI: 52.3–60.8) and did not differ between
RUX pretreatment or no pretreatment: 59.2% (95% CI:
53.3–65.1) vs. 53.7% (95% CI: 47.6–59.8) (p= 0.18). But
EFS was significantly improved in RUX patients with
ongoing spleen response (68.9%) (95% CI: 59.2–78.7) vs.
those without RUX pretreatment (53.7%) (95% CI:
47.6–59.8) and those with no/lost response (49.9%) (95%
CI: 40.2–59.6) (p= 0.01) (Table 3 and Fig. 3). In a MVA
the HR of RUX vs. no-RUX pretreatment was 0.81 (95%
CI: 0.59–1.11) (p= 0.19) (Table 4A), while ongoing spleen
response vs. no/lost response showed a HR of 0.55 (95%
CI: 0.37–0.81) (p= 0.003) and ongoing spleen response vs.
non-RUX showed a HR of 0.61 (95% CI: 0.40–0.91) (p=
0.02). Other significant factors for EFS in the MVA were
age >58 y (HR 1.48; 95% CI: 1.12–1.97, p= 0.006) and
HLA-mismatched donor (HR 1.87; 95% CI: 1.06–3.28, p=
0.03) (Table 4C).
Overall survival
The OS for the entire study population at 2 years was 63.2%
(95% CI: 55.0–66.6) and did not differ between RUX
pretreatment or no pretreatment: 65.5% (95% CI:
59.8–71.1) vs. 60.8% (95% CI: 55.0–66.6) (p= 0.22), and
did also not differ in a univariate analysis between the no-
RUX (60.8%, 95% CI: 55.0–66.6) vs. no/lost response to
RUX (57.5%, 95% CI: 48.0–67.1) and the RUX responsive
group (70.0%, 95% CI: 60.5–79.5) (p= 0.15) (Table 3 and
Fig. 4). In a MVA for OS including RUX vs. non-RUX
pretreatment the HR for RUX pretreatment was 0.81 (95%
CI: 0.59–1.13) (p= 0.21) (Table 4D), while ongoing spleen
response vs. no/lost response showed a HR of 0.69 (95%
CI: 0.42–1.11) (p= 0.12) and ongoing spleen response vs.
non-RUX showed a HR of 0.76 (95% CI: 0.50–1.17) (p=
0.21). The only significant factors in the MVA for OS were
age >58 y (HR 1.42; 95% CI: 1.04–1.95, p= 0.03) and
HLA-mismatched donor (HR 2.37; 95% CI: 1.40–4.03, p=
0.001) (Table 4D). It is of note that the interval between
diagnosis and transplant did not influence survival.
Discussion
The therapeutic effect of JAK-inhibition to reduce spleen
size and improve constitutional symptoms and performance
status is the rationale for using the drug pretransplant and
improve outcome after HSCT for myelofibrosis. Several
smaller retrospective and prospective studies investigated
RUX as pretreatment prior to allogeneic stem cell trans-
plantation with controversial results [13–20]. In two studies
[13, 15] outcome after HSCT was particularly improved in
patients with clinical improvement to RUX therapy while
other reported side effects such as withdrawal symptom or
an increased risk of infections [15, 16, 19], relative high
incidence of graft failure [20] or in one prospective study
tumor lysis syndrome, cardiogenic shock and sepsis [19].
The results of this large retrospective EBMT study con-
firmed safety and feasibility of using RUX prior to HSCT
and supports the expert recommendation regarding the use
of JAK-inhibitor RUX in the context of stem cell trans-
plantation [21]. The majority of the centers followed the
EBMT/ELN recommendations regarding discontinuation of
RUX and only in 6% of the patients a rebound phenomenon
after discontinuation of RUX were reported. However, none
of these events were reported to be life threatening or
required intensive treatment.
We observed a low risk of graft failure in patients who
responded regarding spleen size to RUX prior to trans-
plantation (6%) in comparison to RUX pretreated patients
with no or lost spleen response prior to HSCT (15%), which
highlights the role of spleen size regarding risk of graft
failure in myelofibrosis patients [22]. This is further sup-
ported by 7% graft failure incidence of the non-RUX pre-
treated patients who had only a median spleen size of 8 cm
at time of HSCT.
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The presented large study which included 551 patients
confirmed higher age and mismatched unrelated donors as
significant factors for worse outcome, as shown by several
prospective and retrospective studies [23–30]. In general the
hazard ratio in RUX pretreated patients for NRM, relapse,
EFS, and OS was always <1.0 ranging from 0.68 to 0.81,
but did not reach statistical significance for these outcome
variables. However, if the RUX pretreated patients were
divided in patients with ongoing spleen response at time of
transplantation and no or lost spleen response a clear benefit
could be seen in a lower relapse rate which resulted in an
improved EFS for patients who underwent HSCT with
ongoing spleen response during RUX therapy. Furthermore,
even if not significant (p= 0.07), patients with ongoing
spleen response had a lower NRM rate with only 15% and
an HR of 0.56 in MVA, further supporting the recom-
mendation to transplant myelofibrosis patients with ongoing
spleen response during RUX therapy rather than waiting
until JAK inhibition treatment has failed. However, reduced
relapse rate, lower NRM, and improved EFS did not
translate into a significantly improved OS at 2 years, most
likely because relapse can either be salvaged by donor
Table 4 A Multivariate analysis for non-relapse mortality. B Multivariate analysis for relapse incidence. C Multivariate analysis for event-free
survival. D Multivariate analysis for overall survival.
Ruxolitinib pretreated yes vs. no Ruxolitinib split according to the response
Factor HR (95% CI) p value Factor HR (95% CI) p value
RUX vs. No RUX 0.80 (0.51–1.25) 0.323 Ongoing vs. no/lost spleen response 0.56 (0.30–1.04) 0.069
Age: ≥58 vs. <58 1.40 (0.95–2.04) 0.086 Ongoing spleen response vs. No RUX 0.66 (0.36–1.20) 0.172
DIPSS: High vs. Other 1.13 (0.66–1.96) 0.651 No/lost response vs. No RUX 1.17 (0.62–2.20) 0.626
DIPSS: Missing vs. Other 1.19 (0.70–2.03) 0.525 Age: ≥58 vs <58 1.46 (0.97–2.21) 0.071
Unrelated vs. matched donor 1.73 (1.08–2.76) 0.023 DIPSS: High vs Other 1.08 (0.61–1.92) 0.781
Mismatched vs. matched donor 3.43 (1.86–6.32) <0.01 DIPSS: Missing vs. Other 1.52 (0.85–2.72) 0.160
Unrelated vs. matched donor 1.55 (0.95–2.52) 0.077
Mismatched vs. matched donor 2.79 (1.45–5.36) 0.002
RUX vs. No RUX 0.68 (0.41–1.11) 0.121 Ongoing vs. no/lost spleen response 0.41 (0.15–1.09) 0.073
Age: ≥58 vs. <58 1.23 (0.83–1.83) 0.300 Ongoing spleen response vs. No RUX 0.34 (0.12–0.95) 0.039
DIPSS: High vs. Other 1.08 (0.73–1.58) 0.713 No/lost response vs. No RUX 0.83 (0.51–1.34) 0.449
DIPSS: Missing vs. Other 0.67 (0.40–1.12) 0.128 Age: ≥58 vs. <58 1.34 (0.91–1.96) 0.133
Unrelated vs. matched donor 0.80 (0.44–1.46) 0.467 DIPSS: High vs. Other 1.06 (0.66–1.70) 0.809
Mismatched vs. matched donor 0.65 (0.20–2.13) 0.474 DIPSS: Missing vs. Other 0.71 (0.38–1.31) 0.273
Unrelated vs. matched donor 0.84 (0.42–1.66) 0.615
Mismatched vs. matched donor 0.62 (0.16–2.44) 0.495
RUX vs. No RUX 0.81 (0.59–1.11) 0.196 Ongoing vs. no/lost spleen response 0.55 (0.37–0.81) 0.003
Age: ≥58 vs. <58 1.41 (1.10–1.80) 0.007 Ongoing spleen response vs. No RUX 0.61 (0.40–0.91) 0.016
DIPSS: High vs. Other 1.07 (0.74–1.53) 0.727 No/lost response vs. No RUX 1.11 (0.69–1.77) 0.676
DIPSS: Missing vs. Other 0.95 (0.69–1.29) 0.725 Age: ≥58 vs. <58 1.48 (1.12–1.97) 0.006
Unrelated vs. matched donor 1.18 (0.79–1.74) 0.422 DIPSS: High vs. Other 1.00 (0.70–1.44) 0.982
Mismatched vs. matched donor 1.94 (1.12–1.80) 0.017 DIPSS: Missing vs. Other 1.08 (0.79–1.47) 0.635
Interval Diagnosis-Transplant: +1 month 1.00 (1.00–1.00) 0.903 Unrelated vs. matched donor 1.16 (0.76–1.77) 0.493
Mismatched vs. matched donor 1.87 (1.06–3.28) 0.030
Interval Diagnosis-Transplant: +1 month 1.00 (1.00–1.00) 0.983
Ruxolitinib vs. No Ruxo 0.81 (0.59–1.13) 0.215 Ongoing vs. no/lost spleen response 0.69 (0.42–1.11) 0.123
Age: ≥58 vs. <58 1.37 (1.05–1.78) 0.021 Ongoing spleen response vs. No Ruxo 0.76 (0.50–1.17) 0.212
DIPSS: High vs. Other 1.19 (0.80–1.79) 0.391 No/lost response vs. No Ruxo 1.11 (0.67–1.85) 0.688
DIPSS: Missing vs. Other 1.10 (0.74–1.65) 0.629 Age: ≥58 vs. <58 1.42 (1.04–1.95) 0.026
Unrelated vs. matched donor 1.47 (1.02–2.12) 0.039 DIPSS: High vs. Other 1.16 (0.77–1.74) 0.485
Mismatched vs. matched donor 2.46 (1.45–4.19) 0.001 DIPSS: Missing vs. Other 1.27 (0.87–1.86) 0.216
Interval Diagnosis-Transplant: +1 month 1.00 (1.00–1.00) 0.536 Unrelated vs. matched donor 1.35 (0.92–2.00) 0.128
Mismatched vs. matched donor 2.37 (1.40–4.03) 0.001
Interval Diagnosis-Transplant: +1 month 1.00 (1.00–1.00) 0.464
Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem. . .
lymphocyte infusion and/or second allograft, and a larger
follow-up is needed for valid conclusion regarding differ-
ences in OS [31, 32]. An immunosuppressive effect of RUX
has been described and affects mainly dendritic cells and T-
cell populations [13, 33]. The drug has been investigated in
steroid refractory acute GVHD and has shown higher
response rate at day 28 in a randomized comparison to best
available therapy [34]. In a smaller pilot study given RUX
during transplant period a low incidence of acute GVHD
has been described [35]. In our study no effect of RUX on
the incidence of acute GVHD could be seen, most likely
because of the short half-life of the drug which has been
discontinued many days prior to graft infusion. The
observed non-significant higher incidence of chronic
GVHD in the RUX pretreated group might be best
explained by the higher number of unrelated donor trans-
plantation in the RUX arm.
Due to immunosuppressive effect some studies observed a
higher incidence of CMV reactivation after HSCT in patients
who received RUX prior to transplant and it is of interest that
also in our study a higher but not significant incidence of
CMV reactivation (36.6% vs. 26.8%) was observed in the
RUX-pretreated CMV seropositive patients [15].
In our study we observed different lengths of time
interval between diagnosis and transplantation in both arms
with a considerable longer interval in the RUX pretreated
arm, which is in line with a recent real world report on RUX
treatment showing prolonged treatment even in patients
with unstable or no spleen response. This suggested a
delaying transplant strategy rather than a bridging strategy
[36]. However, by using several statistical methods
including left truncation or Poisson model we could not
confirm that the variable time from diagnosis to transplant
had any impact on event-free or OS in our study population.
Although if other JAK inhibitors like fedratinib, pacritinib,
or momelotinib have shown some activity in RUX pre-
treated patients [37–39] the outcome after RUX-failure is
poor. A large retrospective US population-based study
showed for myelofibrosis patients after RUX discontinua-
tion an OS of only 11.1 months [40]. Even if our study
suggests better outcome in RUX responders than in those
who discontinued RUX because of loss of response the 2-
year survival is still about 60% after allografting in patients
who failed to RUX. Whether these results can be improved
by using a second-line JAK-inhibitor prior to transplant to
reduce spleen size after RUX failure has to be shown in a
prospective trial. Another concern of postponing transplant
by continuing RUX therapy until treatment failure is the
observed risk of clonal evolution during RUX treatment by
acquiring new mutations [41]. The median duration of RUX
in myelofibrosis in the literature is about 3 years but the
drug is discontinued due to loss of response or side effects
[7, 8, 42].
Our study has some limitations. Due to its retrospective
nature, the selection process that decided which patient
received RUX prior to stem cell transplantation and which
patient was scheduled for transplantation at spleen response
Fig. 2 Relapse incidence after stem cell transplantation according
Ruxo pretreatment. Cumulative incidence of relapse after allogeneic
stem cell transplantation of RUX responder vs. no/lost responders vs.
non-RUX pretreatment.
Fig. 3 Event-free survival after stem cell transplantation according
Ruxo pretreatment. Event-free survival after allogeneic stem cell
transplantation of RUX responder vs. no/lost responders vs. non-RUX
pretreatment.
Fig. 4 Overall survival after stem cell transplantation according
Ruxo pretreatment. Overall survival after allogeneic stem cell
transplantation of RUX responder vs. no/lost responders vs. non-RUX
pretreatment.
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or after RUX failure is unknown. It is likely that selection to
RUX treatment was based on spleen size which was at a
median 12 cm in the RUX pretreatment group and only 8
cm in the non-RUX group. Furthermore, despite the trend
for improved outcome for RUX pretreated patients, other
factors could drive the results instead of treatment exposure.
However, it should be noted that unfavorable factors such
as DIPPS intermediate II/high risk and Karnofsky ≤ 80 were
more seen in the RUX pretreated group.
In conclusion this large retrospective study showed feasi-
bility of using RUX prior to allogeneic stem cell transplan-
tation in myelofibrosis with no negative impact on NRM, RI,
event-free and OS post-transplant. In particular a significant
lower graft failure incidence rate was observed in RUX
responders in comparison to RUX failure and a significantly
lower relapse rate and improved EFS was seen for those who
received stem cell transplant with ongoing spleen response to
RUX in comparison to non-RUX treated patients.
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